Browse > Article
http://dx.doi.org/10.3904/kjm.2012.83.5.619

A Case of Acute Hepatitis B by Occult HBV Infection without HbsAg Seroconversion  

Jung, Hye Mi (Department of Internal Medicine, Hanyang University School of Medicine)
Jun, Dae Won (Department of Internal Medicine, Hanyang University School of Medicine)
Min, Ji Yeon (Department of Internal Medicine, Hanyang University School of Medicine)
Doo, Eun Young (Department of Internal Medicine, Hanyang University School of Medicine)
Nam, Kil Woo (Department of Internal Medicine, Hanyang University School of Medicine)
Kwon, Young Il (Department of Internal Medicine, Hanyang University School of Medicine)
Kwon, Oh Wan (Department of Internal Medicine, Hanyang University School of Medicine)
Publication Information
The Korean Journal of Medicine / v.83, no.5, 2012 , pp. 619-623 More about this Journal
Abstract
Many studies have recently reported reactivation in hepatitis B surface antigen (HBsAg)-negative subjects with the use of biologic agents such as rituximab. However, occult hepatitis B virus infection itself has little clinical impact. We experienced a case of acute exacerbation caused by occult hepatitis B infection without HBsAg seroconversion. No mutation was found on the major hydrophilic loop of the S protein. The patient recovered from acute exacerbation after antiviral therapy. In conclusion, acute exacerbation can be induced by occult hepatitis B virus infection itself without reactivation. In such a case, antiviral therapy should be considered.
Keywords
Hepatitis B Surface Antigens; Hepatitis B; Rituximab;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.   DOI   ScienceOn
2 Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 2010;55:3328-3335.   DOI   ScienceOn
3 Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-191.   DOI   ScienceOn
4 Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004;11:18-25.   DOI   ScienceOn
5 Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-657.   DOI   ScienceOn
6 Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-1857.
7 Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-2259.
8 Bruss V, Vieluf K. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J Virol 1995;69:6652-6657.
9 Schweizer J, Valenza-Schaerly P, Goret F, Pourcel C. Control of expression and methylation of a hepatitis B virus transgene by strain-specific modifiers. DNA Cell Biol 1998;17:427-435.   DOI   ScienceOn
10 Cha CH, Sohn YH, Ko SY, Oh HB. Subgenotype and serotype analysis of hepatitis B virus in Korean chronic hepatitis B patients under treatment. Korean J Lab Med 2009;29:53-58.   DOI   ScienceOn